Key result
Agomelatine shows high efficacy and good tolerability for depression in patients with CVD.
Why the study?
Depression frequently co-occurs with cardiovascular diseases and worsens clinical characteristics, making timely detection and psychopharmacotherapy clinically and prognostically important.
Agomelatine is highlighted as an effective and well-tolerated antidepressant for patients with cardiovascular diseases, potentially avoiding adverse drug interactions via CYP450.
May support agomelatine in depressed CVD patients; leaves open confirmation in prospective CV outcome trials.
Depression is the most common form of mental illness in patients with cardiovascular diseases (CVD). Depression and CVD can worsen the clinical and dynamic characteristics of each other. The timely detection and adequate psychopharmacotherapy of depressive states in patients with CVD are of great clinical, therapeutic, and prognostic importance. Anti-antidepressant therapy promotes a more pronounced somatic stabilizing effect in patients with CVD. Adverse events to the use of antidepressants in patients with CVD may be associated with their negative effect on the hepatic cytochrome CYP450 isoenzymes involved in the metabolism of various drugs. The authors' own data of clinical psychopharmacotherapeutic studies and the results of meta-analyses indicate the high efficiency and good tolerability of agomelatine, an antidepressant with an innovative mechanism of action, in a wide range of patients
No takes yet. Share an insight, caveat, or question.
Korovyakova et al. (2019) conducted a review in Cardiovascular diseases and depression. Antidepressant therapy (agomelatine) was evaluated. Agomelatine demonstrated high efficiency and good tolerability in patients with cardiovascular diseases and depression, based on clinical studies and meta-analyses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: